A Multicenter, Randomized, Double Blind, Controlled Study on the Prevention of Nausea and Vomiting after Weight Loss Surgery by Injecting Anisodamine at Zusanli Point

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065749

Enrollment

Unknown

Registered

2022-11-14

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic disease

Interventions

C group:Routine prevention+Zusanli injection of normal saline

S group:Routine prevention+injection of anisodamine into Zusanli

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) ASA grade I~III; (2) Female patients aged 18-65 years undergoing elective gastric volume reduction surgery under general anesthesia; (3) Informed consent of patients.

Exclusion criteria

Exclusion criteria: (1) Contraindications of percutaneous acupoint injection, such as local rash or systemic infection of the skin stimulated by acupoints; (2) Combined with known drug allergy related to this study, severe heart, respiratory, kidney or liver diseases; (3) Coagulation dysfunction; (4) Psychiatric or nervous system diseases; (5) Difficulty in communication; (6) Pre medication or pre-existing medical conditions prior to surgery limit the objective evaluation, including the use of antiemetics, opioids or glucocorticoids; (7) Gastroesophageal reflux.

Design outcomes

Primary

Measure	Time frame
Evaluation of postoperative nausea and vomiting, and use of remedial antiemetic drugs;	—

Countries

China

Contacts

Public ContactZhiping Wang/ Ye Zhang

Affiliated Hospital of Xuzhou Medical University

zhpsqxt@126.com13338787071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026